Free shipping on all orders over $ 500

Obinutuzumab

Cat. No. M1615

All AbMole products are for research use only, cannot be used for human consumption.

Obinutuzumab Structure
Synonym:

afutuzumab; GA101

Size Price Availability Quantity
2mg USD 560  USD560 In stock
5mg USD 800  USD800 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Obinutuzumab (GA101) is a fully humanized monoclonal antibody that binds to an epitope on CD20. Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.

Chemical Information
Molecular Weight 146062.27
Formula C6512H10060N1712O2020S44
CAS Number 949142-50-1
Form Liquid
Storage -80°C for long term
References

[1] Evans SS, et al. J Adv Pract Oncol. Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia.

[2] Herting F, et al. Leuk Lymphoma. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma.

[3] Decaup E, et al. Blood Cancer J. Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model.

[4] Herter S, et al. Mol Cancer Ther. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

Related CD20 Products
Ofatumumab

Ofatumumab is a humanised anti-CD20 monoclonal antibody, which appears to inhibit early-stage B lymphocyte activation.

Rituximab

Rituximab is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD.

Glofitamab

Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma.

Ripertamab

Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL).

Zuberitamab

Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma.

  Catalog
Abmole Inhibitor Catalog




Keywords: Obinutuzumab, afutuzumab; GA101 supplier, CD20, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.